SG10201704716XA - Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders - Google Patents
Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other DisordersInfo
- Publication number
- SG10201704716XA SG10201704716XA SG10201704716XA SG10201704716XA SG10201704716XA SG 10201704716X A SG10201704716X A SG 10201704716XA SG 10201704716X A SG10201704716X A SG 10201704716XA SG 10201704716X A SG10201704716X A SG 10201704716XA SG 10201704716X A SG10201704716X A SG 10201704716XA
- Authority
- SG
- Singapore
- Prior art keywords
- metformin
- diabetes
- disorders
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201704716XA true SG10201704716XA (en) | 2017-07-28 |
Family
ID=50030537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201504778UA SG11201504778UA (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
| SG10201704716XA SG10201704716XA (en) | 2013-01-17 | 2014-01-14 | Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201504778UA SG11201504778UA (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (en) |
| EP (1) | EP2945618B1 (en) |
| JP (1) | JP6445459B2 (en) |
| KR (1) | KR102165434B1 (en) |
| CN (1) | CN104968341B (en) |
| AU (1) | AU2014207748B2 (en) |
| CA (1) | CA2896308C (en) |
| EA (1) | EA201591123A1 (en) |
| ES (1) | ES2687083T3 (en) |
| HK (1) | HK1210424A1 (en) |
| IL (1) | IL239714A0 (en) |
| MX (1) | MX366685B (en) |
| SG (2) | SG11201504778UA (en) |
| WO (1) | WO2014113357A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002977A (en) | 2017-09-22 | 2020-11-06 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof. |
| KR20210005843A (en) * | 2018-05-08 | 2021-01-15 | 브이티브이 테라퓨틱스 엘엘씨 | Therapeutic uses of GLP1R agonists |
| WO2021196949A1 (en) * | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Crystalline form a of glp-1 receptor agonist and preparation method therefor |
| CN115315426B (en) * | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Pharmaceutically acceptable acid salts of GLP-1 receptor agonist free base and methods of making the same |
| US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| KR20080086442A (en) * | 2005-11-07 | 2008-09-25 | 일릭서 파마슈티컬즈, 인크. | Combinations of metformin and meglitinide |
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| EA023430B1 (en) * | 2009-03-30 | 2016-06-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
| WO2011031620A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| ES2534191T3 (en) * | 2009-11-13 | 2015-04-20 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
-
2014
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/en active Active
- 2014-01-14 EA EA201591123A patent/EA201591123A1/en unknown
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/en active Active
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/en active IP Right Grant
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/en active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en active Application Filing
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 MX MX2015008555A patent/MX366685B/en active IP Right Grant
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
- 2015-11-13 HK HK15111246.2A patent/HK1210424A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2896308C (en) | 2021-11-09 |
| EP2945618B1 (en) | 2018-06-13 |
| MX366685B (en) | 2019-07-19 |
| IL239714A0 (en) | 2015-08-31 |
| ES2687083T3 (en) | 2018-10-23 |
| MX2015008555A (en) | 2016-01-22 |
| AU2014207748A1 (en) | 2015-07-09 |
| CN104968341A (en) | 2015-10-07 |
| AU2014207748B2 (en) | 2018-10-11 |
| SG11201504778UA (en) | 2015-07-30 |
| CN104968341B (en) | 2020-06-09 |
| HK1210424A1 (en) | 2016-04-22 |
| EP2945618A1 (en) | 2015-11-25 |
| KR102165434B1 (en) | 2020-10-14 |
| CA2896308A1 (en) | 2014-07-24 |
| WO2014113357A1 (en) | 2014-07-24 |
| US20150313908A1 (en) | 2015-11-05 |
| KR20150104572A (en) | 2015-09-15 |
| EA201591123A1 (en) | 2015-11-30 |
| JP2016505039A (en) | 2016-02-18 |
| JP6445459B2 (en) | 2018-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181296T1 (en) | Substituted benzamides for the treatment of arthropods | |
| HRP20190528T1 (en) | Evaluation, assays and treatment of pkal-mediated disorders | |
| HK1226084A1 (en) | Gip and glp-1 receptor dual-agonists for the treatment of diabetes | |
| IL240285A0 (en) | Type 2 diabetes biomarkers and uses thereof | |
| PT3811943T (en) | Compound for use in the treatment of ocular disorders | |
| PL3046470T3 (en) | Diagnosing and treating movement disorders | |
| PL2968218T3 (en) | Combination for the treatment of parkinson's disease | |
| IL243572B (en) | A pharmaceutical combination for the treatment of melanoma | |
| IL238027A0 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders | |
| GB2519982B (en) | Fungicidal composition and the use thereof | |
| HK1210424A1 (en) | Combinations of a glpir agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders glp1r 2 | |
| HRP20190219T1 (en) | Compounds for the treatment of obesity and methods of use thereof | |
| IL241474B (en) | Articulated device for the wrist | |
| PT3041441T (en) | Hand orthosis for supporting the thumb, in particular in case of rhizarthrosis | |
| GB201320506D0 (en) | Cyclic amino compounds for the use in the treatment of cardiac disorders | |
| EP3713604C0 (en) | Compound for use in the increasing of mental capability | |
| GB201800645D0 (en) | Monitoring medication consumption | |
| GB201314183D0 (en) | Status of type 2 diabetes | |
| TWM476976U (en) | Wrist pad | |
| GB201320349D0 (en) | New therapeutic use | |
| TWM476582U (en) | Watch type stethoscope device | |
| GB201303232D0 (en) | Tramadol for the mouth |